Triple single-pill antihypertensive drug combinations: the key to effective blood pressure control

Read full text Summarise with VIRAT
Authors: T E Morozova, Герцог Анна Алексеевна, N. V. Shikh, A. A. Arakelyants
Cited by: 0
References: 45

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Despite the wide selection of antihypertensive medications, blood pressure (BP) control often remains unsatisfactory, and the number of people with uncontrolled hypertension (HTN) increases every year. The aim of this review was to analyze and summarize data from clinical trials and systematic reviews examining the potential of triple singlepill combinations (SPCs) of antihypertensive agents. We focused on amlodipine/indapamide/perindopril combination and its place in the current hypertension treatment strategy. Data are presented demonstrating that triple SPCs represent one of the most effective and safe approaches to hypertension treatment. This SPC of amlodipine/indapamide/perindopril, based on the synergism of complementary mechanisms of action, has one of the most compelling evidence bases among available triple-dose combinations. It can be considered one of the most rational and evidence-based triple therapy options in patients with uncontrolled HTN, particularly those with high cardiovascular risk and the need to rapidly and sustainably achieve target BP levels. Costeffectiveness models have shown that the SPC of amlodipine/indapamide/perindopril can reduce healthcare costs by reducing the incidence of cardiovascular events and hospitalizations while simultaneously increasing life expectancy and quality of life.

Fields of Study & Subjects

Blood Pressure and Hypertension Studies Sodium Intake and Health Cardiovascular Health and Disease Prevention

Publication details

Journal / source
Russian Journal of Cardiology
Volume
31
Issue
2
Pages
6810–6810
Publication date
29 March 2026
Language
EN